Preface content

Our governance

The Pirbright Institute is an independent company, limited by guarantee and a registered charity, governed by a Board of non-executive Trustee Directors. Research at the Institute is reviewed by an independent group of leading scientists who comprise of the Science Advisory Board and whose role it is to provide advice and guidance on science strategy and direction.



Professor Vince Emery (Chair of the Trustee Board)

Vince EmeryProfessor Vince Emery is President of the University of Hertfordshire's branch campus in Egypt and is a Visiting Professor at the University of Hertfordshire, UK. 

Prof Emery graduated with a first class BSc in Biochemistry with Chemistry and PhD from the University of Southampton. His interests in virology started when he undertook a postdoc at the NERC Institute of Virology at Oxford where he worked on developing the world’s first baculovirus multiple expression vector system.

He was appointed Lecturer in Virology in 1988 and received his Professorship at UCL in 2000. His research has aimed to provide an interdisciplinary approach to understanding viral infections in the immunocompromised and in newborns (especially in Africa) with a particular focus on cytomegalovirus infections by combining viral replication assessments, immune responses and mathematical biology. During his career he has obtained in excess of £29 million of grants, has an H-index of 75 and his work has been cited over 20,000 times. Prof Emery has published 238 research articles, reviews, and books.  In addition, Prof Emery is a named inventor on five patents.  

Prof Emery is a fellow of the Royal Society of Biology and a Fellow of the American Society of Transplantation. 

Professor Mike Turner (Deputy Chair of the Trustee Board)

Professor Mike Turner is Deputy Chair of the Board of Trustees and Member of the Risk and Assurance Committee

Mike is a consultant currently working for the Neglected Tropical Diseases department of the WHO in their snakebite initiative. He is Honorary Professor at University of Glasgow UK, a member of council at the London School of Hygiene and Tropical Medicine and on the Science Advisory Board at the Glasgow Centre for Virus Research. He is a former Director of Science and member of the Senior Executive team at Wellcome, Europe’s largest biomedical research foundation. He joined Wellcome in 2014 as Head of Infection and Immunobiology and led on a number of portfolios including funding responses to emerging viral diseases – Ebola, Zika, Yellow Fever and Covid19.

Approximately three quarters of the science funded by Wellcome is based in the UK but Mike had particular responsibilities for Wellcome’s funding in Africa, India and SE Asia as well. Before joining Wellcome he was at the University of Glasgow where he held Beit, Royal Society and Leverhulme Fellowships. Latterly, he became Professor of Parasitology and held a number of managerial roles, including as Head of Division. His research interests focussed on the trypanosome parasites that cause African sleeping sickness in humans and Nagana in livestock, the genomics of malaria parasites and the immunoepidemiology of schistosomes.

Rona Chester (Chair of Finance and Audit Committee)

Rona Chester (Chair of Finance and Audit Committee) Rona Chester is Chair of the Finance & Audit Committee.

Rona is a fellow of the Institute of Chartered Accountants with over 30 years’ experience in leading financial teams in both the public and private sector. During her early career Rona worked in international finance managing the Finance and Treasury teams for an oil and gas shipping business followed by roles at Sotheby’s as their European Finance Director and Ofcom the newly formed communications regulator. More recently Rona was the Chief Operating Officer at Sport England, the lottery distributor, where additional responsibilities included grants management, Commercial and IT as well as contributing to the development of the organisations strategy.

Alison Hardy (Chair of Nominations and Governance Committee)

Alison Hardy is Interim Chair of the Nominations and Governance Committee

Alison Hardy, Trustee of The Pirbright

Alison is a solicitor qualified in England & Wales in 2000, specialising in complex high value commercial real estate disputes.  She is global head of Real Estate Dispute Resolution at City law firm Ashurst LLP,  where she is also a member of the Admissions Committee (a board subcommittee) which interviews lateral partners and internal promotions to partner.  She co-leads the firms' Social Mobility and Inclusion initiative which is working to remove barriers to entry into and progression within the legal profession and regularly speaks on the subject including for the Lord Mayor's Appeal. 

During her legal career she has been chair of the Property Litigation Association, enjoys the Freedom of the City of London, linked to her role as a Freeman of the City of London Solicitors Company, and attends the City of London Solicitors Company Land Law Committee.  

Alison has chaired the UK RICS dilapidations conference for 4 years (2021 – 2024 inclusive). She speaks at conferences and is regularly quoted in both trade publications such as the Estates Gazette and Property Week, and national press such as The Times and The Financial Times. 


Dr Paul Logan (Chair of Risk and Assurance Committee)

Dr Paul Logan, Trustee of The Pirbright InstituteDr Paul Logan is Chair of the Risk & Assurance Committee.

Prior to his retirement in 2020, Paul was a Senior Civil Servant in the Health and Safety Executive (HSE) which he had joined as a regulatory scientist. He subsequently trained as a specialist inspector with responsibility for inspection of high containment laboratories. During his time in HSE he chaired a number of industry/government committees, as well as representing the UK on a European Medicines Agency working group on Gene Therapy, and a World Health Organization group developing guidelines for the manufacture of pandemic flu vaccines. In his final post he was Director of the division in HSE with responsibility for regulation of major hazards industries, including chemical manufacturing, oil refineries, explosives manufacture and storage, and high containment laboratories. 

Jon Coles

Mr Jon Coles, Trustee Board MemberJon Coles is a Member of the Finance & Audit Committee and Nominations and Governance Committee.

Jon was a senior Partner at Brunswick Group LLP, a leading international communications consultancy, where he advised the Boards of Directors of global groups on strategic communications and corporate reputation. His particular focus was on clients in the pharmaceutical, biotechnology and agriculture industries.

Dr Linda Magee OBE

Linda MageeLinda is a life sciences sector specialist in the UK Government’s Department for Business and Trade. She supports the UK sector team and international network to identify opportunities for the UK economy and businesses in life sciences and healthcare.

Prior to her current position Linda was Chief Operations Officer of the NIHR Manchester Academic Health Science Centre (MAHSC), a national centre of excellence for translational medicine, and Commercial Director of the NHS Greater Manchester Academic Health Science Network (GMAHSN), part of a national network dedicated to the adoption of innovation into the NHS.

Linda was co-founder and General Manager of Manchester Biotech Ltd, the UK’s first dedicated campus based biotechnology incubator company and later set up Bionow®, a biomedical cluster organisation, while the Northwest Development Agency’s Sector Director for Life Sciences. In this role she also established the National Biomanufacturing Centre at Speke, now a commercial biopharmaceutical facility. 

Following a PhD in Medical Biochemistry at the University of Southampton, Linda worked for a multinational healthcare company in technical and marketing positions. She was awarded an OBE in 2009 for services to biotechnology.

Professor Deenan Pillay

Professor Deenan Pillay is the Board of Trustee Directors representative to the Science Advisory Board

Deenan Pillay wearing a green jumper located in his home office

Deenan is Emeritus Professor of Virology at University College London. He has been a clinical virologist for the last 30 years, working within the Public Health Laboratory Service, Health Protection Agency, NHS and academia. His main interest has been the use of antiviral therapy, and emergence of drug resistance, particularly regarding HIV. From 2013-2019 he was Director/CEO of the Wellcome Trust-funded Africa Health Research Institute, an independent institute based in Kwa Zulu Natal in South Africa focused on laboratory, clinical and population approaches to HIV and TB. He is currently Non-Executive Director of an NHS Trust, and until recently Chaired Independent SAGE, a scientific group focused on public engagement and discussion on COVID. 

Jane Tirard

 Jane Tirard Trustee Board member at Pirbright Jane Tirard is a Member of the Finance & Audit Committee.

Jane has over 30 years of experience of all aspects of strategic financial planning, financial management, financial accounting, systems and processes. As a result of her roles she has a working knowledge of government departments, funding councils, academia and the pharmaceutical industry. Her last position was as the Director of Finance and Corporate Services at the Diamond Light Source, the UK’s national synchrotron science facility.

Tamsin Webster

Tamsin WebsterTamsin has held a number of senior level roles in HR in SME's and global corporates including BlackRock, UBS and Lloyds Banking Group. In her current role at Fulcrum Asset Management, she oversees the entire employee lifecycle which includes recruitment, performance management, talent development, remuneration and learning and development. Tamsin works closely with the Diversity Project who a driving change across the Asset Management industry on all aspects of diversity, equity and inclusion.

Tamsin is an experienced leadership coach and brings the knowledge of leadership development, employee engagement, organisation design and governance to create the structure and capability needed to support business transformation, at all stages of growth or transition. Tamsin has built a strong understanding of working in regulatory environments having worked in Financial Services and the Telecoms industry during times of significant change.  Tamsin is a qualified project manager, has a degree in Psychology from University of Kent, a MA in Coaching and a MSc in Viticulture and Oenology.

Professor Geoffrey L. Smith (Chair)

 Professor Geoffrey L. SmithGeoffrey L. Smith is Professor of Pathology at the University of Cambridge. He obtained his PhD (1981) for work with influenza virus in Alan Hay’s laboratory at NIMR, London. Then as a postdoc in Bernard Moss’s laboratory at NIH, USA (1981-84), together with Michael Mackett, he developed vaccinia virus (the smallpox vaccine) as an expression vector and established the principal of using genetically engineered viruses as live vaccines. He continued working with poxviruses in UK at Cambridge (1985-9), Oxford (1989-2000), Imperial College London (2000-11) and since 2011 back in Cambridge. His research studies the interactions of poxviruses with the host cell and immune system.

Current external roles include Chairmanship of the WHO Advisory Committee for Variola Virus (smallpox) Research (2004-) and the Scientific Advisory Board of the Centre for Structural and Systems Biology, Hamburg, and a member of the University Research Grants Council, Hong Kong. Formerly, he was President of IUMS, Chairman of the Royal Society Committee for Scientific Aspects of International Security, Chairman of the Scientific Advisory Board of the Friedrich-Loeffler Institute (German Ministry for Food and Agriculture), a member of the Royal Society Science Policy Advisory Group, and a Governor of the Lister Institute of Preventive Medicine. He was elected a Fellow of the Academy of Medical Sciences (2002), the Institute of Biology (2002), the Royal Society (2003), a Founding Member of the European Academy of Microbiology (2008) and a member of Leopoldina - the German National Academy of Sciences (2011).

Professor Dr Martin Beer

Prof Dr Martin BeerMartin Beer was born in Erlangen and graduated in veterinary medicine in 1992 in Munich. In 1995, he received his PhD from the Ludwig-Maximilians-University in Munich studying the T-cell immunity against bovine viral diarrhea virus (BVDV). In 2000, Martin Beer moved to the Friedrich-Loeffler-Institut (FLI) as head of the reference laboratory for bovine herpesvirus type 1 infections and continued his work on BVDV and other pestiviruses. Since 2004, he is head of the Institute of Diagnostic Virology at the FLI, working with transboundary animal diseases, zoonosis and emerging diseases like avian influenza virus, Schmallenberg virus or bornaviruses. Modern diagnostics, molecular epidemiology and pathogenesis studies with transboundary viral diseases (e.g Bluetongue Disease virus and African swine fever virus) and viral zoonoses (e.g. poxviruses and influenza viruses) are a major focus of his research since more than 20 years. For selected viruses, also the development of strategies for immunoprophylaxis is an important research goal. A special feature is the work with animals including livestock animals under BLS3 and BSL4 (animal) conditions. During the past years, especially workflows for virus discovery using next-generation sequencing (NGS) based metagenomics were developed and several new viruses could be identified and further characterized. NGS was also used to generate whole-genomes of important viruses for phylogeny and molecular epidemiology. In addition, new vaccine strategies were developed, e.g. for classical swine fever virus or avian influenza viruses.

Professor Persephone Borrow

Professor Persephone BorrowProfessor Persephone Borrow is a viral immunologist whose research interests centre on understanding virus-immune system interactions and their roles in determining the balance between virus clearance versus viral persistence and associated pathogenesis.

She obtained a BA(Hons) degree in Natural Sciences from the University of Cambridge, UK and stayed at Cambridge to study for a PhD under the supervision of Professor Tony Nash. After this she carried out postdoctoral research with Professor Michael Oldstone at The Scripps Research Institute, USA, where she subsequently progressed to become an Assistant Member. She then returned to the UK to lead the Viral Immunology Group at the newly-established Edward Jenner Institute for Vaccine Research, and in 2005 joined the Nuffield Department of Medicine at the University of Oxford, where she currently holds the position of Professor of Viral Immunology and is also a Jenner Institute Investigator.

Her research team, based at the NDM Research Building on Oxford University’s Old Road Campus, focuses mainly on analysis of CD4 and CD8 T cell responses and innate responses in HIV infection, aiming to inform the development of vaccines and other prophylactic and therapeutic strategies based on modulation of T cell and innate immunity; and is also performing some comparative studies of innate responses in other human virus infections including herpesvirus infections.  Her group’s research is largely funded by the MRC and the US NIH. 

Professor Mary Cameron

Mary Cameron Mary Cameron is a Professor of Medical Entomology in the Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM). She obtained a BSc in Zoology in 1983, and a PhD in Entomology in 1987, from the University of London.

Mary has over 30 years’ experience in delivering international level field and laboratory research focusing on the surveillance and control of a wide range of vector-borne diseases, particularly leishmaniasis. During this time, Mary has developed strong collaborative networks on neglected tropical diseases in multiple disease endemic countries. She is presently the Principal Investigator of the Bill and Melinda Gates Programme: Setting the Post-Elimination Agenda for Kala-azar in India (SPEAK India). The focus of the operational research is to work towards sustained elimination of visceral leishmaniasis in the Indian Sub-continent. The work comprises four synergistic pillars: surveillance, mathematical modelling, disease transmission and health systems.

In addition, Mary is currently a member of the steering committees of the MRC-funded research project ‘The epidemiology of scrub typhus and rickettisial infections in a highly endemic rural setting in South India: population-based cohort study’, and the BBSRC-funded ‘The Global Vector Hub’. Until July 2021, Mary was Co-Director of a BBSRC GCRF network ‘The Gnatwork: building capacity for research on neglected tropical vectors’ (with Dr Simon Carpenter, The Pirbright Institute). 

Externally, Mary has held several societal advisory roles and was Editor-in-Chief of Medical and Veterinary Entomology (2012-2020). Current roles include Member of the WHO Regional Technical Advisory Group to support the Kala-azar elimination programme in the South-East Asia Region (since 2017) and External Examiner for MSc Global Health Course (University of Edinburgh) (since 2018). Mary is a co-founder and Director of LSHTM’s first spin out company, Vecotech Ltd, which serves as a vehicle to support commercial exploitation of intellectual property generated by vector control research at LSHTM and other academic organisations. The company is now operating as Arctech Innovation Ltd.

Professor Gary Entrican

Professor Gary Entrican, member of Pirbright's Science Advisory BoardProfessor Gary Entrican is an immunologist who has specialised in the development of vaccines and diagnostic tests for the control of infectious diseases of ruminant livestock. He did his BSc Hons and PhD in Immunology at The University of Glasgow and then moved to The Moredun Research Institute (MRI) in Edinburgh to investigate the immunological basis of pestivirus persistence in sheep. He has developed many immunological tools and technologies, including kits for in vitro differentiation of ruminant dendritic cells and cytokine ELISAs. He produced a panel of pestivirus-specific monoclonal antibodies and developed a first-generation diagnostic ELISA employed in the bovine viral diarrhoea virus (BVDV) eradication programme in Scandinavia in the 1990s.

For most of his time at MRI he led a team investigating chlamydial abortion in sheep and identification of Th1-type responses as immune correlates of protection for novel sub-unit vaccine design. He managed a cross-Institute Work Package within the Scottish Government Strategic Research Programme until his departure from MRI in 2019.   

Gary was awarded an Honorary Professorship within the College of Medicine and Veterinary Medicine at The University of Edinburgh in 2008, a position he still holds. He has been active in a number of Committees, including Chair of the International Union of Immunological Societies Veterinary Immunology Committee (2013-2019). He is currently a member of the Scientific Committee of the STAR-IDAZ International Research Consortium (2017-2022) and Congress Secretary of the British Society for Immunology (2017-2021) and maintains his interests in vaccinology and ruminant immunology.

Professor Paul Kellam

Paul KellamPaul is Professor of Virus Genomics in the Department of Medicine at Imperial College London. Paul’s scientific career has spanned industry, at the Wellcome Foundation Ltd, Kymab Ltd and RQ Biotechnology Ltd, and academia, where Paul was the Virus Genomics lead at the Wellcome Trust Sanger Institute, a Professor of Virology at UCL and is Professor of Virus Genomics at Imperial College London. He has published extensively, was elected as a Fellow of the American Academy of Microbiology in 2015 and was the scientific advisor to the UKs COVID-19 Vaccine Task Force.

Paul’s research career has identified how HIV develops resistance to antiviral drugs and identified the first influenza disease severity gene in people hospitalised with influenza virus. His laboratory produced the virus genome analysis of the Middle East Respiratory Syndrome Coronavirus (MERS CoV) outbreaks working with the Department of Health in Saudi Arabia, showing that the transmission pattern of the virus was consistent with multiple transfer events from an animal reservoir and contributing to the identification of camels as the animal reservoir. His laboratory contributed to the international Ebola virus genome analysis to help the WHO control the outbreak and to show the factors influencing virus transmission. Paul’s work on B cell repertoires has showed how the application of genetics and computational biology can give insights into infectious and non-infectious disease biology and leads to the discovery of antibodies to treat infections, such as SARS-CoV-2.

Professor Deenan Pillay

Deenan is Emeritus Professor of Virology at University College London. He has been a clinical virologist for the last 30 years, working within the Public Health Laboratory Service, Health Protection Agency, NHS and academia. His main interest has been the use of antiviral therapy, and emergence of drug resistance, particularly regarding HIV. From 2013-2019 he was Director/CEO of the Wellcome Trust-funded Africa Health Research Institute, an independent institute based in Kwa Zulu Natal in South Africa focused on laboratory, clinical and population approaches to HIV and TB. He is currently Non-Executive Director of an NHS Trust, and until recently Chaired Independent SAGE, a scientific group focused on public engagement and discussion on COVID. 

Eleanor M. Riley, BSc, BVSc, PhD, FRSB, FMedSci

 Eleanor Riley After graduating from Bristol University with degrees in cellular pathology and veterinary medicine, Eleanor interned in veterinary pathology at Cornell University and obtained her PhD in immunology and parasitology from the University of Liverpool.  After 5 years at the Medical Research Council Laboratories in The Gambia, Eleanor moved to the University of Edinburgh as a Wellcome Trust Senior Research Fellow. She was appointed to a personal chair in immunology of infectious diseases at the London School of Hygiene and Tropical Medicine in 1998 where she was head of the Department of Immunology and Infection and deputy director of the Malaria Centre. In September 2017, Eleanor moved back to University of Edinburgh to take up the role of Director of the Roslin Institute. In 2020, she moved to the School of Biological Sciences in the College of Science and Engineering.

Eleanor’s research focusses on mechanisms of immunity to malaria in humans and in animal models, how the immune response can contribute to disease, how immunity affects the distribution and transmission of the parasite and how malaria infection affects resistance to other infections. In addition, Eleanor has a longstanding interest in the biology of natural killer (NK) cells and their role in resistance to infection.

Eleanor is a fellow of the Royal Society of Edinburgh and the Academy of Medical Sciences and has previously served as Committee and Strategy Panel chair at BBSRC and as deputy chair of the MRC Infections and Immunity Board. She is currently a member of the governing Council of the MRC, was recently elected to the governing Council the Academy of Medical Sciences and is a member of the advisory board of the Science Media Centre.

Professor David Rowlands

Professor Rowlands is an emeritus Professor of Molecular Virology at the University of Leeds. He worked at the Animal Virus Research Institute (now The Pirbright Institute), before transferring to industry, holding positions at Wellcome Biotech and the Wellcome Foundation and finally moved into academia at the University of Leeds. He has a lifetime of experience studying both human and animal viruses. 

Professor Helen Sang

Professor Helen Sang Helen Sang received a degree in Natural Sciences and PhD in genetics from Cambridge University. She continued developing a research career with the award of an SERC-NATO Fellowship held at Harvard University and an MRC Fellowship held at Edinburgh University.

Helen was then appointed as a Principal Investigator at The Roslin Institute, now part of the University of Edinburgh. Her main research focus at The Roslin Institute has been the development of technologies for genetic modification of the chicken, which are applied in basic biomedical research, biotechnology and investigating the potential for developing disease resistance in production chickens. Professor Helen Sang was appointed Personal Chair in Vertebrate Molecular Development in 2009. Her research has been supported by grants from the BBSRC, MRC, Wellcome Trust and industry.

In addition to her research, Helen has a strong commitment to Public Engagement with Research and lead the Roslin Institute’s Athena SWAN (gender equality) activities, resulting in achieving a gold award. Helen has been a member of several BBSRC committees and BBSRC Council, and is currently a member of the UKRI-BBSRC’s Appointments Board. She is a Fellow of the Royal Society of Biology and the Royal Society of Edinburgh and was awarded an OBE in 2019 for services to food security and bioscience for health.

Dr Samuel Thevasagayam

Samuel Thevasagayam Samuel Thevasagayam leads the Livestock initiative within the Agriculture Development Program at the Bill & Melinda Gates Foundation where he oversees the implementation of foundation’s strategy in animal health, animal production and livestock systems. Sam joined the Gates Foundation in 2012.

Samuel started his career as a small animal clinician and lecturer at the University of Peradeniya, Sri Lanka. He then went on to work in academic research, Pharmaceutical R&D (veterinary and human), Business Development and within the not-for profit sector, living and working in four continents before joining the Gates Foundation.  

Samuel graduated from the faculty of Veterinary Medicine and Animal Sciences of the University of Peradeniya, Sri Lanka. Gained his PhD in veterinary virology from the University of Hertfordshire for his research on foot-and-mouth disease virus at The Pirbright Institute and holds an MBA from the University of Oxford. He is a Charted Biologist and a Fellow of the Royal Society of Biology.

Trim content

® The Pirbright Institute 2024 | A company limited by guarantee, registered in England no. 559784. The Institute is also a registered charity.